ReviewIndian journal of pharmacology
Current advances in transdermal delivery of drugs for Alzheimer's disease.
Review in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Traditional Chinese Medicines for Alzheimer's Disease: Current Knowledge, Clinical Applications, and Future Directions.Current topics in medicinal chemistry · 2026Review
- Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.Acta neurologica Belgica · 2025Review
- Recent Advances in Donepezil Delivery Systems via the Nose-to-Brain Pathway.Pharmaceutics · 2025Review
- Optimizing Neuroprotective Nano-structured Lipid Carriers for Transdermal Delivery through Artificial Neural Network.Pharmaceutical nanotechnology · 2025Article
- The Multifaceted S100B Protein: A Role in Obesity and Diabetes?International journal of molecular sciences · 2024Review
- Imaging Methods Applicable in the Diagnostics of Alzheimer's Disease, Considering the Involvement of Insulin Resistance.International journal of molecular sciences · 2023Review
- Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer's Disease.Brain sciences · 2023Review
- Digital Intervention for the Management of Alzheimer's Disease.Current Alzheimer research · 2022Review
- Microneedles in diagnostic, treatment and theranostics: An advancement in minimally-invasive delivery system.Biomedical microdevices · 2021Review
- Neuroprotective effects of theTranslational neuroscience · 2021Article
- Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.Advances in experimental medicine and biology · 2021Review
- Characterisation of Drug Delivery Efficacy Using Microstructure-Assisted Application of a Range of APIs.Pharmaceutics · 2020Article
- Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease.Drug delivery · 2020Article
- Role of Insulin Resistance in the Alzheimer's Disease Progression.Neurochemical research · 2020Review
- Type 3 Diabetes and Its Role Implications in Alzheimer's Disease.International journal of molecular sciences · 2020Review
- Article
- Genetic analyses of early-onset Alzheimer's disease using next generation sequencing.Scientific reports · 2019Article
- Analysis of 50 Neurodegenerative Genes in Clinically Diagnosed Early-Onset Alzheimer's Disease.International journal of molecular sciences · 2019Article
- Epitope Mapping Immunoassay Analysis of the Interaction between β-Amyloid and Fibrinogen.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a common, progressive, fatal neurodegenerative disorder, which will play an increasingly important role both socially and financially in the aging populations. Treatments for AD show modest improvements in cognition and global functioning among patients. Furthermore, the oral administration of treating AD has had some drawbacks that decrease the medication adherence and efficacy of the therapy. Transdermal drugs are proposed as an alternative remedy to overcome the disadvantages of current pharmaceutical dosage options for this chronic disorder. They could have different strengths, such as offering a stable diffusion of active substance, avoiding the first pass metabolism, and reducing system adverse reactions. This article reviews the technical principles, novel techniques of transdermal delivery drug, and prospects for future development for the management of cognitive and behavioral dysfunctions in AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.